Lakefront Biotherapeutics Buys Back 97,497 Shares Under Ongoing Repurchase Program
I'm LongbridgeAI, I can summarize articles.Lakefront Biotherapeutics (formerly Galapagos) repurchased 97,497 shares between July 27-31, 2026, at an average price of €24.48, totaling approximately €2.39 million. This action is part of its ongoing share buyback program announced in June. Following the transactions, the company holds 704,216 treasury shares. The move reflects management's confidence and supports shareholder returns, despite a current 'Sell' analyst rating with a EUR22.00 price target.
Galapagos ( (NL:LKFT) ) has issued an announcement.
Lakefront Biotherapeutics has continued executing its share repurchase program announced in June, buying back 97,497 shares between July 27 and July 31, 2026 through an independent financial intermediary across several European trading venues. The purchases were made at an average price of €24.48 per share, for a total consideration of about €2.39 million, reflecting ongoing capital deployment in support of its shareholder return strategy.
Following these transactions, Lakefront holds 704,216 of its own ordinary shares as of market close on July 31, 2026, modestly increasing the proportion of treasury stock on its balance sheet. The buybacks underscore management’s confidence in the company’s valuation and financial position, and may provide incremental support to the share price while slightly enhancing earnings per share for remaining investors over time.
The most recent analyst rating on (NL:LKFT) stock is a Sell
with a EUR22.00 price target.
To see the full list of analyst forecasts on Galapagos stock,
see the NL:LKFT Stock Forecast page.
More about Galapagos
Lakefront Biotherapeutics, formerly known as Galapagos, is a biotechnology company focused on developing a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. Its clinical‑stage portfolio centers on immunology and inflammation, led by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune indications, supported by strong deal‑making capabilities and capital resources.
The company targets high‑quality therapeutic assets with clear potential for meaningful patient benefit and long‑term shareholder value. Lakefront leverages operational flexibility and its dual listing on Euronext and Nasdaq to support its growth strategy and maintain visibility among global biotech investors.
Average Trading Volume: 74,824
Technical Sentiment Signal: Strong Sell
Current Market Cap: €1.57B
For an in-depth examination of LKFT stock, go to TipRanks’ Overview page.